Ivermectin, a Nobel Prize-winning antiparasitic, has become one of the most discussed repurposed drugs in experimental oncology. As preclinical research continues to identify anti-tumor and immune-modulating mechanisms, and a Phase I/II clinical trial at Cedars-Sinai actively tests it alongside immunotherapy, one of the most common questions people ask is: "What dose of ivermectin is used in cancer protocols?"

This guide covers ivermectin dosage considerations in the context of investigational cancer use, common dosing patterns found in research and experimental protocols, bioavailability factors, safety concerns, and why careful dose management matters more than maximizing intake.

What Is Ivermectin?

Ivermectin is a broad-spectrum antiparasitic agent derived from the bacterium Streptomyces avermitilis. Since its introduction in the 1980s, it has been administered billions of times worldwide to treat river blindness, lymphatic filariasis, and strongyloidiasis. It is included on the WHO Model List of Essential Medicines and its developers received the 2015 Nobel Prize in Physiology or Medicine.

In recent years, preclinical research has identified several mechanisms by which ivermectin may interact with tumor biology — including inhibition of PAK1 kinase, disruption of WNT-TCF signaling, induction of immunogenic cell death, and modulation of the tumor microenvironment. A 2020 review in Pharmacological Research documented these anti-tumor mechanisms across multiple cancer cell lines (PMC7505114). For a full overview of ivermectin's medical uses and emerging oncology research, see our detailed article: Ivermectin and Cancer Immunotherapy: What the Research Shows.

Standard Antiparasitic Dosage vs. Investigational Oncology Use

For approved antiparasitic indications, ivermectin is typically prescribed at a single dose of 0.15–0.2 mg/kg body weight. For a 70 kg adult, this translates to approximately 10.5–14 mg as a one-time dose, repeated only as directed for specific parasitic conditions. At these doses, ivermectin has decades of well-documented safety data.

Investigational oncology protocols use different dosing strategies — often higher doses, repeated schedules, and pulsed cycling patterns. These are not FDA-approved dosing guidelines and remain strictly experimental. The rationale is that sustained or repeated exposure may be needed to achieve the anti-tumor concentrations observed in preclinical models, though it is important to recognize that laboratory concentrations often exceed what is achievable with standard oral dosing.

A 2021 pharmacokinetic study published in the Journal of Pharmaceutical Sciences examined ivermectin absorption in humans and noted that oral bioavailability is moderate, with peak plasma concentrations reached approximately 4–5 hours after ingestion and a half-life of roughly 18 hours (PMC8248985). This pharmacokinetic profile informs the pulsed dosing schedules used in experimental settings.

⚠️Important: There are no FDA-approved dosing guidelines for ivermectin in cancer treatment. All oncology-related protocols are considered experimental and off-label. Always discuss with a qualified healthcare provider before starting any protocol.

Dosing Patterns in Experimental Cancer Protocols

Unlike the single-dose antiparasitic regimen, investigational oncology use of ivermectin involves repeated, pulsed dosing over extended periods. The two most referenced frameworks are the ISOM Protocol and the Cedars-Sinai clinical trial NCT05318469.

The ISOM Hybrid Orthomolecular Protocol, published in 2024 by researchers affiliated with the International Society for Orthomolecular Medicine, recommends ivermectin at 0.2–0.4 mg/kg body weight, taken 2–3 times per week, often on fasting days. For a 70 kg adult, this translates to approximately 14–28 mg per dose. The protocol uses ivermectin alongside other repurposed agents including fenbendazole, vitamin C, and curcumin as part of a broader metabolic strategy. For a complete breakdown, see our article: ISOM Protocol: A Modern Metabolic Strategy Using Repurposed Drugs.

The Phase I/II clinical trial NCT05318469 at Cedars-Sinai Medical Center uses a more intensive pulsed schedule within 21-day treatment cycles. Participants receive oral ivermectin on Days 1–3, 8–10, and 15–17 of each cycle — nine days of dosing per three-week cycle — combined with an immune checkpoint inhibitor administered intravenously on Day 1. This trial represents the first structured human study to formally test ivermectin as an immunotherapy adjunct and is designed to establish both safety parameters and preliminary efficacy signals. For a detailed analysis of this trial, see: Can Ivermectin Enhance Immunotherapy? Inside Trial NCT05318469.

Some community-driven protocols use simpler schedules, such as 0.2 mg/kg taken once or twice weekly, or 3 days on / 4 days off patterns — similar in concept to the cycling approach used in the widely known Joe Tippens Protocol for fenbendazole. These anecdotal approaches lack clinical validation but reflect common self-reported patterns.

Bioavailability: What Affects Absorption?

One of the most important — and often overlooked — factors in ivermectin dosing is bioavailability. Ivermectin is a highly lipophilic compound, meaning it dissolves in fat rather than water. Research consistently shows that taking ivermectin with a high-fat meal significantly increases absorption compared to fasting administration.

A well-cited pharmacokinetic study demonstrated that ivermectin taken with a fatty meal achieved approximately 2.5 times higher plasma concentrations compared to fasting conditions. This means the same dose can produce substantially different blood levels depending on whether it is taken with or without food.

For this reason, most experimental protocols recommend taking ivermectin with meals that include healthy fats — such as avocado, nuts, olive oil, eggs, or fatty fish. This practical consideration can meaningfully affect how much of the compound reaches systemic circulation and potentially target tissues.

Other factors that influence ivermectin bioavailability include individual variation in liver metabolism (ivermectin is primarily metabolized by CYP3A4 enzymes), body composition, age, and concurrent medications that may inhibit or induce CYP3A4 activity.

Signs You Might Be Taking Too Much Ivermectin

While ivermectin has a well-established safety record at approved antiparasitic doses, repeated or higher-dose use in experimental settings carries additional considerations. Based on pharmacological data and reported experiences, signs of overuse or intolerance may include:

Nausea or abdominal discomfort

Dizziness or lightheadedness

Diarrhea

Headaches or visual disturbances

Fatigue or weakness

Tremor or coordination difficulties (at significantly elevated doses)

Ivermectin is metabolized primarily by the liver through CYP3A4 enzymes. Extended use at higher-than-approved doses can increase hepatic load, particularly when combined with other compounds that share the same metabolic pathway. Periodic liver function testing (ALT, AST, bilirubin) is recommended during any extended experimental protocol.

If symptoms emerge or worsen during use, this may signal the need to reduce dosage, extend the off-cycle period, or pause the protocol entirely. The goal of any dosing strategy should be tolerability and sustainability — not maximizing the amount taken.

Critical Drug Interactions and Safety Warnings

Ivermectin's metabolism through the CYP3A4 enzyme system means it can interact with a range of other medications. This is particularly relevant for cancer patients who may be taking multiple drugs simultaneously.

CYP3A4 inhibitors — such as ketoconazole, itraconazole, erythromycin, and grapefruit juice — can significantly increase ivermectin blood levels by slowing its breakdown. This raises the risk of dose-dependent side effects even at otherwise tolerable doses.

CYP3A4 inducers — such as rifampin, carbamazepine, and phenytoin — can reduce ivermectin levels, potentially making it less effective.

Warfarin and other anticoagulants may interact with ivermectin, requiring closer monitoring of INR values.

Additionally, ivermectin should be used with extreme caution in patients with compromised blood-brain barrier integrity. Under normal conditions, P-glycoprotein at the blood-brain barrier limits ivermectin's entry into the central nervous system. However, conditions that impair this barrier — including certain brain tumors, meningitis, or concurrent P-glycoprotein inhibitors — may increase CNS exposure and the risk of neurotoxicity.

When ivermectin is used alongside other repurposed agents such as fenbendazole, curcumin, or methylene blue, the cumulative hepatic load must be considered. This is especially important within multi-agent frameworks like the ISOM Protocol, where several compounds share overlapping metabolic pathways. For a direct comparison of the two most commonly discussed antiparasitics, see: Fenbendazole vs. Ivermectin: Comparing Safety, Strength, and Effectiveness.

Monitoring and Bloodwork During Extended Use

Anyone using ivermectin as part of an extended experimental protocol should prioritize regular bloodwork and clinical monitoring. Key markers to track include:

Liver function panel (ALT, AST, GGT, bilirubin) — to detect hepatic stress before symptoms appear

Complete blood count (CBC) — to monitor white blood cells, red blood cells, and platelets

Kidney function (creatinine, BUN) — particularly important in patients with pre-existing renal conditions

General symptom tracking — energy levels, digestion, cognitive clarity, and any new or worsening symptoms during on-cycles and off-cycles

A baseline panel before starting any protocol is strongly recommended, with follow-up testing every 4–8 weeks depending on dosage intensity and individual risk factors. This approach allows dose adjustments to be guided by objective data rather than subjective guesswork.

Why More Isn't Always Better

Ivermectin's proposed anti-cancer mechanisms — including PAK1 inhibition, WNT pathway disruption, and induction of immunogenic cell death — operate through specific molecular interactions, not through brute-force cytotoxicity. Flooding the body with excessive doses does not necessarily amplify these effects and may instead create additional toxicity burden without therapeutic benefit.

The concept of a therapeutic window is critical: there is a range within which the compound may exert its intended biological effects. Below this range, exposure may be insufficient. Above it, side effects increase without proportional benefit. This is why the Cedars-Sinai clinical trial includes a dose-escalation phase — to carefully identify the optimal balance between efficacy signals and tolerability.

Rather than maximizing dose from the outset, a titration approach is more consistent with pharmacological principles:

Start at the lower end of experimental dosing (0.2 mg/kg, once or twice per week) and observe tolerability for 1–2 weeks

Gradually increase frequency or dose if well tolerated, guided by both subjective symptoms and bloodwork

Incorporate regular off-cycles to allow hepatic recovery and reduce cumulative exposure

Consider the full protocol context — if you are also taking fenbendazole, curcumin, or other compounds, each adds to the total metabolic load

For readers interested in real-world experiences from people using these products, visit our Customer Notes & Experiences page.

Key Takeaways

Standard antiparasitic dosing (0.15–0.2 mg/kg single dose) differs significantly from investigational oncology use (0.2–0.4 mg/kg, multiple times per week)

The ISOM Protocol recommends 0.2–0.4 mg/kg taken 2–3 times weekly; the Cedars-Sinai trial uses 9 days of dosing per 21-day cycle

Bioavailability increases substantially when taken with dietary fat — up to 2.5x higher plasma levels compared to fasting

CYP3A4 drug interactions can significantly alter ivermectin blood levels — review all concurrent medications

Regular liver function monitoring and bloodwork are essential during extended experimental use

Titration is key — start low, observe your response, and adjust gradually based on both symptoms and objective markers

Ivermectin is not an FDA-approved cancer treatment and remains investigational in oncology

Always consult a qualified healthcare professional before beginning any off-label protocol

Scientific References

Tang M, et al. (2020). Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacological Research, 163, 105207. PMC7505114

Draganov D, et al. (2021). Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade. Frontiers in Pharmacology. PMC8419571

Guerini AE, et al. (2021). Ivermectin and cancer: An analysis of cancer incidence in populations using ivermectin. eClinicalMedicine (Lancet). PMC8248985

González Canga A, et al. (2008). The pharmacokinetics and interactions of ivermectin in humans — a mini-review. AAPS Journal, 10(1), 42–46. PMC2751445

ClinicalTrials.gov — NCT05318469: Ivermectin + Immunotherapy in Metastatic TNBC

Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice. Do not self-prescribe. Always consult a qualified healthcare provider before using any medication or supplement.

Below are commonly referenced items mentioned in this article. Links are provided for convenience — always review the label and consult a professional before use.

Ivermectin 6 / 12 / 18 mg — 100 tablets

Buy Ivermectin →

Fenbendazole 222 mg 180 capsules — 99% purity, laboratory tested

Buy Fenbendazole 222 →

Curcumin Turmeric 360 mg 120 capsules — with Black Pepper & Phytosome for absorption

Buy Curcumin →

Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.